Trial Profile
Phase II Study of AZD2171 (NSC 732208) in Combination With Pemetrexed in Relapsed Non-Small Cell Lung Cancer (NOS: 10029514)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2018
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Jan 2013 Planned End Date changed from 1 Mar 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 28 Nov 2012 Planned end date changed from 1 Dec 2010 to 1 Mar 2012 as reported by ClinicalTrials.gov.
- 16 Mar 2012 Planned End Date changed from 1 Jul 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.